TARS Tarsus Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TARS

Price (delayed)

$36.85

Market cap

$1.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.62

Enterprise value

$1.07B

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline ...

Highlights
Tarsus Pharmaceuticals's gross profit has decreased by 36% YoY but it has increased by 17% from the previous quarter
The company's revenue fell by 32% YoY but it rose by 21% QoQ
The company's net income has shrunk by 119% YoY and by 26% QoQ
The company's EPS has shrunk by 83% YoY and by 21% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tarsusrx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of TARS
Market
Shares outstanding
34.22M
Market cap
$1.26B
Enterprise value
$1.07B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.19
Price to sales (P/S)
62.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
61.09
Earnings
Revenue
$17.45M
EBIT
-$132.55M
EBITDA
-$131.13M
Free cash flow
-$123M
Per share
EPS
-$4.62
Free cash flow per share
-$4.19
Book value per share
$5.95
Revenue per share
$0.59
TBVPS
$8.9
Balance sheet
Total assets
$265.49M
Total liabilities
$68.5M
Debt
$29.82M
Equity
$196.99M
Working capital
$219.2M
Liquidity
Debt to equity
0.15
Current ratio
6.93
Quick ratio
6.64
Net debt/EBITDA
1.49
Margins
EBITDA margin
-751.6%
Gross margin
90.9%
Net margin
-778.9%
Operating margin
-820.5%
Efficiency
Return on assets
-58.2%
Return on equity
-74.3%
Return on invested capital
-164.6%
Return on capital employed
-58%
Return on sales
-759.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TARS stock price

How has the Tarsus Pharmaceuticals stock price performed over time
Intraday
6.41%
1 week
15.01%
1 month
2.7%
1 year
143.88%
YTD
81.98%
QTD
1.38%

Financial performance

How have Tarsus Pharmaceuticals's revenue and profit performed over time
Revenue
$17.45M
Gross profit
$15.85M
Operating income
-$143.16M
Net income
-$135.89M
Gross margin
90.9%
Net margin
-778.9%
TARS's operating income has shrunk by 128% YoY and by 26% QoQ
The company's net income has shrunk by 119% YoY and by 26% QoQ
Tarsus Pharmaceuticals's gross profit has decreased by 36% YoY but it has increased by 17% from the previous quarter
The company's revenue fell by 32% YoY but it rose by 21% QoQ

Growth

What is Tarsus Pharmaceuticals's growth rate over time

Valuation

What is Tarsus Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.19
P/S
62.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
61.09
The company's EPS has shrunk by 83% YoY and by 21% QoQ
TARS's P/B is 121% above its last 4 quarters average of 2.8
The company's equity fell by 8% QoQ but it rose by 2.1% YoY
The P/S is 102% higher than the last 4 quarters average of 30.7
The company's revenue fell by 32% YoY but it rose by 21% QoQ

Efficiency

How efficient is Tarsus Pharmaceuticals business performance
TARS's ROE has plunged by 129% YoY and by 26% from the previous quarter
The ROA has plunged by 111% YoY and by 21% from the previous quarter
TARS's return on invested capital has dropped by 79% year-on-year and by 78% since the previous quarter
The company's return on sales fell by 4.4% QoQ

Dividends

What is TARS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TARS.

Financial health

How did Tarsus Pharmaceuticals financials performed over time
Tarsus Pharmaceuticals's total liabilities has soared by 96% YoY and by 25% from the previous quarter
The company's quick ratio has shrunk by 54% YoY and by 39% QoQ
Tarsus Pharmaceuticals's debt is 85% lower than its equity
Tarsus Pharmaceuticals's debt has surged by 53% YoY
The debt to equity has soared by 50% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.